Australia's most trusted
source of pharma news
Tuesday, 30 June 2026
Posted 30 June 2026 AM
CSL's Tavneos looks set to be withdrawn from European distribution, after regulators there changed their minds about the decision to recommend the drug.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the EU marketing authorisation for CSL's auto-immune drug, Tavneos. With the opinion provided, the final decision is up to the European Commission and is expected shortly.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.